Literature DB >> 34471938

Cytokine adsorption in severe, refractory septic shock.

Pedro David Wendel Garcia1, Matthias Peter Hilty1, Ulrike Held2, Eva-Maria Kleinert1, Marco Maggiorini3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34471938      PMCID: PMC8409473          DOI: 10.1007/s00134-021-06512-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, Septic shock and the underlying dysregulated inflammatory host-response remain major contributors to mortality in critically ill patients. In contrast to classic hemofiltration strategies, cytokine adsorption through bulk removal of cytokines has been postulated to re-establish inflammatory homeostasis, representing an attractive approach to the treatment of septic shock [1]. Nonetheless, most evidence to date is of descriptive or ambivalent character and cytokine adsorption in severe, refractory septic shock is largely unexplored [2]. To investigate the effect of cytokine adsorption on circulating interleukin (IL)-6, vasopressor requirements and intensive care mortality, patients presenting with severe, refractory septic shock, IL-6 ≥ 1000 ng/l and a vasopressor dependency index ≥ 3, despite adequate volume resuscitation, were prospectively recruited. Cytokine adsorption was provided for three consecutive 24-h sessions initiated within 24 h from shock onset. Forty-eight included patients were matched to 160 patients having fulfilled the same severe, refractory septic shock criteria (e-Fig. 1). Six matching algorithms were evaluated against each other to achieve optimal balancing of covariates, leading to the choice of Genetic Matching as superior algorithm. For further specifications on the employed methodology, see e-Appendix 1. The baseline characteristics among the 96 matched patients (48 treated with cytokine adsorption, 48 treated without) were equivalent (e-Table 1, e-Fig. 2). Patients were characterized by a SOFA score of 14 ± 3, profound lactatemia (5.8 ± 4.8 mmol/l) and required 0.7 ± 0.5 µg/kg/min norepinephrine. Within the 72-h intervention period, circulating IL-6 levels (p = 0.254) and vasopressor requirements (p = 0.555) decreased irrespective of cytokine adsorption use (Fig. 1a, b, e-Table 2, e-Fig. 3). Intensive care mortality was more pronounced in patients treated with cytokine adsorption than in the control group (control: 20 (42%), cytokine adsorption: 32 (67%), p = 0.024) as evidenced by a competing risks hazard ratio for mortality of 1.82 (95% confidence interval, 1.03–3.2; p = 0.038) (Fig. 1c). Additional analyses are presented in e-Appendix 2.
Fig. 1

Primary end points. Temporal development of (a) interleukin-6 levels and (b) the vasopressor dependency index. Depicted are notched box plots with median and interquartile range, and whiskers extending from the difference of the first quartile and 1.5 times the interquartile range, to the sum of the third quartile and 1.5 times the interquartile range. Notches represent the 95% confidence interval of the median. The x-axis portrays the time in hours ensuing severe, refractory septic shock onset. (c) Kaplan–Meier curves for 30-day intensive care unit survival stratified by control and cytokine adsorption group, plotted in blue and red colors, respectively. Shaded areas represent the 95% confidence interval. The x-axis portrays the time in days ensuing severe, refractory septic shock onset. The computed hazard ratio assesses the cytokine adsorption group using the control group as reference. The 95% confidence interval is given in parentheses. Hazard ratios were modeled by means of a Fine and Gray competing risk analysis. Censoring reflects patients having left the intensive care unit alive. The underlying table presents the patients at risk per time point with the number of censored patients given in parentheses

Primary end points. Temporal development of (a) interleukin-6 levels and (b) the vasopressor dependency index. Depicted are notched box plots with median and interquartile range, and whiskers extending from the difference of the first quartile and 1.5 times the interquartile range, to the sum of the third quartile and 1.5 times the interquartile range. Notches represent the 95% confidence interval of the median. The x-axis portrays the time in hours ensuing severe, refractory septic shock onset. (c) Kaplan–Meier curves for 30-day intensive care unit survival stratified by control and cytokine adsorption group, plotted in blue and red colors, respectively. Shaded areas represent the 95% confidence interval. The x-axis portrays the time in days ensuing severe, refractory septic shock onset. The computed hazard ratio assesses the cytokine adsorption group using the control group as reference. The 95% confidence interval is given in parentheses. Hazard ratios were modeled by means of a Fine and Gray competing risk analysis. Censoring reflects patients having left the intensive care unit alive. The underlying table presents the patients at risk per time point with the number of censored patients given in parentheses For almost four decades, the hypothesis that quantitative removal of inflammatory mediators improves survival in sepsis has resulted in negative trials [2]. Unexpectedly however, our data reflect the results of the first multicenter trial having assessed cytokine adsorption in sepsis [3] and, despite the pathophysiological differences, of a recent trial assessing cytokine adsorption in severe patients affected by coronavirus disease 2019 (COVID-19) on extracorporeal membrane oxygenation [4]. It evidenced not only no effect of cytokine adsorption on circulating IL-6 levels, but also strikingly suggested an increased mortality in the cytokine adsorption group. Cytokines play a pivotal role in the progression of host response in sepsis. Pro-inflammatory cytokines may be associated with a deranged host response and poor outcomes during early sepsis. However, nothing persists for millions of years if it does not offer a substantial evolutionary benefit. Indeed, the dynamic interplay between pro- and anti-inflammatory cytokines is imperative to achieve tissue repair, endothelial integrity and resolution of inflammation. Indiscriminate removal of cytokines could thus lead to a perpetuation of inflammation and prothrombogenicity, leading to sustained microcirculatory and mitochondrial dysfunction, ultimately promoting end-organ damage and death [5]. In conclusion, cytokine adsorption in severe, refractory septic shock was neither associated with reduced IL-6 levels nor vasopressor requirements, and lead to an increased hazard of death. The present results in conjunction with recent evidence plead against the widespread and indiscriminate use of cytokine adsorption outside of investigational settings and urge for a return to qualitative and mechanistic blood purification research in septic shock. Below is the link to the electronic supplementary material. Supplementary file1 (PDF 2262 KB)
  5 in total

1.  Hemoadsorption with CytoSorb®.

Authors:  Elettra C Poli; Thomas Rimmelé; Antoine G Schneider
Journal:  Intensive Care Med       Date:  2018-11-16       Impact factor: 17.440

Review 2.  Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review.

Authors:  Anthony Bonavia; Andrew Groff; Kunal Karamchandani; Kai Singbartl
Journal:  Blood Purif       Date:  2018-09-03       Impact factor: 2.614

3.  The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial.

Authors:  Dirk Schädler; Christine Pausch; Daniel Heise; Andreas Meier-Hellmann; Jörg Brederlau; Norbert Weiler; Gernot Marx; Christian Putensen; Claudia Spies; Achim Jörres; Michael Quintel; Christoph Engel; John A Kellum; Martin K Kuhlmann
Journal:  PLoS One       Date:  2017-10-30       Impact factor: 3.240

Review 4.  Cytokine removal in human septic shock: Where are we and where are we going?

Authors:  Patrick M Honore; Eric Hoste; Zsolt Molnár; Rita Jacobs; Olivier Joannes-Boyau; Manu L N G Malbrain; Lui G Forni
Journal:  Ann Intensive Care       Date:  2019-05-14       Impact factor: 6.925

5.  Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.

Authors:  Alexander Supady; Enya Weber; Marina Rieder; Achim Lother; Tim Niklaus; Timm Zahn; Franziska Frech; Sissi Müller; Moritz Kuhl; Christoph Benk; Sven Maier; Georg Trummer; Annabelle Flügler; Kirsten Krüger; Asieb Sekandarzad; Peter Stachon; Viviane Zotzmann; Christoph Bode; Paul M Biever; Dawid Staudacher; Tobias Wengenmayer; Erika Graf; Daniel Duerschmied
Journal:  Lancet Respir Med       Date:  2021-05-14       Impact factor: 30.700

  5 in total
  5 in total

1.  Extracorporeal immune cell therapy of sepsis: ex vivo results.

Authors:  Gerd Klinkmann; Thomas Wild; Benjamin Heskamp; Fanny Doss; Sandra Doss; Lubomir Arseniev; Krasimira Aleksandrova; Martin Sauer; Daniel A Reuter; Steffen Mitzner; Jens Altrichter
Journal:  Intensive Care Med Exp       Date:  2022-06-16

2.  Unraveling the secret of re-balancing homeostasis in sepsis: a critical view on extracorporeal blood purification modalities.

Authors:  Klaus Stahl; Pedro David Wendel-Garcia; Christian Bode; Sascha David
Journal:  Intensive Care Med       Date:  2021-10-28       Impact factor: 17.440

Review 3.  The Effects of Hemoadsorption on the Kinetics of Antibacterial and Antifungal Agents.

Authors:  Giorgio Berlot; Stefano Di Bella; Ariella Tomasini; Erik Roman-Pognuz
Journal:  Antibiotics (Basel)       Date:  2022-01-29

Review 4.  Hemoperfusion in the intensive care unit.

Authors:  Zaccaria Ricci; Stefano Romagnoli; Thiago Reis; Rinaldo Bellomo; Claudio Ronco
Journal:  Intensive Care Med       Date:  2022-08-19       Impact factor: 41.787

5.  Application of oXiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: A single-centre experience in China.

Authors:  Yanyan Zhou; Chenfang Wu; Lin Ouyang; Ying Peng; Dingming Zhong; Xiaohong Xiang; Jinxiu Li
Journal:  Front Public Health       Date:  2022-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.